Osimertinib in NSCLC: Real-World Data From New Zealand

INTRODUCTION: EGFR tyrosine kinase inhibitors (TKIs) are more effective than chemotherapy in patients with EGFR-mutant NSCLC. Disease progression on EGFR TKI therapy occurs most often owing to acquired resistance from the gain of an EGFR T790M mutation. Osimertinib, a third-generation EGFR TKI, sign...

Descripción completa

Detalles Bibliográficos
Autores principales: So, Yeojeong Jane, Fraser, Anne, Rivalland, Gareth, McKeage, Mark, Sullivan, Richard, Cameron, Laird
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2020
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8474409/
https://www.ncbi.nlm.nih.gov/pubmed/34589929
http://dx.doi.org/10.1016/j.jtocrr.2020.100022

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8474409/
https://www.ncbi.nlm.nih.gov/pubmed/34589929
http://dx.doi.org/10.1016/j.jtocrr.2020.100022

Ejemplares similares